VC-backed Graphite Bio raises $238m for IPO
Graphite Bio, a gene editing company focused on treating or curing serious diseases, has raised $238 million for its IPO after pricing its 14 million shares at $17 per share.
Graphite Bio, a gene editing company focused on treating or curing serious diseases, has raised $238 million for its IPO after pricing its 14 million shares at $17 per share.
Copyright PEI Media
Not for publication, email or dissemination